Treatment of COPD with Pulmonary Artery Hypertension

Primary Treatment Approach

The American Thoracic Society recommends that drugs approved for primary pulmonary arterial hypertension (PAH) are NOT recommended for patients with pulmonary hypertension secondary to COPD 1
The European Respiratory Society suggests that long-acting bronchodilators form the foundation of therapy, with long-acting muscarinic antagonist (LAMA) monotherapy as the preferred first-line bronchodilator 2
The American College of Chest Physicians recommends that combination LABA/LAMA therapy should be used from the outset for severe disease 3, 1

The European Respiratory Society states that LTOT is the only intervention proven to improve survival and partially reduce progression of pulmonary hypertension in COPD 4, 5, 6
The European Respiratory Society recommends prescribing LTOT when PaO2 ≤7.3 kPa (55 mmHg) during a stable 3-4 week period despite optimal therapy 4
The American College of Chest Physicians suggests maintaining oxygen saturations >90% at all times (rest, sleep, and exertion) 7, 5
The European Respiratory Society recommends using oxygen for minimum 15 hours daily, with continuous use providing greater survival benefit 4

The European Respiratory Society recommends using diuretics carefully to reduce peripheral edema and ascites, but avoid excessive diuresis that may reduce cardiac output and cause renal hypoperfusion 4
The European Respiratory Society suggests monitoring for electrolyte imbalances, as the hypoxic myocardium is particularly sensitive to metabolic disturbances 4

The American Thoracic Society states that there is no evidence that pulmonary vasodilators have any role in COPD with pulmonary hypertension 3
The European Respiratory Society recommends avoiding conventional vasodilators like calcium channel blockers as they impair gas exchange by inhibiting hypoxic pulmonary vasoconstriction and lack long-term efficacy 6
The American College of Chest Physicians suggests that drugs approved for PAH should not be used, as there is no evidence from randomized controlled trials showing improved symptoms or outcomes in lung disease 1, 6

The American College of Chest Physicians recommends considering anticoagulation with warfarin in COPD patients with pulmonary hypertension, though evidence is weaker than for idiopathic PAH 7, 8
The European Respiratory Society suggests influenza and pneumococcal vaccination to prevent respiratory infections that can precipitate acute decompensation 4, 8
The American Thoracic Society recommends pulmonary rehabilitation for patients with high symptom burden to improve exercise capacity and quality of life 1, 5
The European Respiratory Society suggests nutritional support for underweight patients (BMI <21 kg/m²), as weight loss contributes to morbidity and mortality 5

The American Thoracic Society recommends not empirically prescribing PAH-specific medications without documented severe, disproportionate pulmonary hypertension on right heart catheterization 1, 6
The European Respiratory Society suggests not using calcium channel blockers without vasoreactivity testing, as they worsen ventilation-perfusion matching in COPD 6
The European Respiratory Society recommends not prescribing oxygen without arterial blood gas confirmation of hypoxemia, and reassess need if prescribed during an exacerbation 5
The American College of Chest Physicians suggests avoiding beta-blockers (including eye drops) as they can worsen bronchospasm 3